Document 0775
 DOCN  M9470775
 TI    [The antiviral action of recombinant forms of the human T-lymphocyte CD4
       receptor]
 DT    9409
 AU    Zverev VV; Maliushova VV; Sidorov AV; Pugach AV; Shukhmina NR; Pille ER;
       Mel'nikova NL; Andzhaparidze OG
 SO    Vopr Virusol. 1994 Mar-Apr;39(2):56-9. Unique Identifier : AIDSLINE
       MED/94287654
 AB    A recombinant protein containing the first 179 N-terminus amino acids of
       human T-lymphocyte CD4-receptor was synthesized in E. coli cells. This
       recombinant protein was shown to interact with OKT4A and Leu3a
       monoclonal antibodies competing with HIV gp120 glycoprotein for binding
       with the native CD4 receptor. Experiments in vitro in human T-lymphocyte
       cultures showed that the recombinant CD4-protein in concentrations of 1
       to 10 micrograms/ml inhibited the virus-induced syncytium formation, HIV
       replication in cell culture, synthesis of HIV reverse transcriptase and
       other virus-specific proteins, that is, behaved as a HIV inhibitor.
 DE    Antibodies, Monoclonal/DRUG EFFECTS/METABOLISM  Antigens, CD4/DRUG
       EFFECTS/IMMUNOLOGY/METABOLISM/*PHARMACOLOGY  Antiviral Agents/CHEMICAL
       SYNTHESIS/*PHARMACOLOGY  Cells, Cultured/DRUG EFFECTS/METABOLISM
       Depression, Chemical  Dose-Response Relationship, Drug  English Abstract
       Giant Cells/DRUG EFFECTS  Human  HIV Envelope Protein gp120/DRUG
       EFFECTS/METABOLISM  HIV-1/*DRUG EFFECTS/METABOLISM  Protein Binding/DRUG
       EFFECTS  Recombinant Proteins/CHEMICAL SYNTHESIS/PHARMACOLOGY  Reverse
       Transcriptase/DRUG EFFECTS  T-Lymphocytes/DRUG EFFECTS/METABOLISM  Virus
       Cultivation  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).